In 2017, a controversy has risen about a potential link between direct acting antiviral (DAA) for hepatitis C and a higher incidence of tumour recurrence after a curative treatment of hepatocellular carcinoma (HCC). This retrospective multicentric American study has analysed 793 patients treated for HCC developed on hepatitis C related cirrhosis and compared 304 patients treated by DAA (42% of tumour relapse) versus 489 untreated patients (58.9% of tumour relapse). After adjustment, DAA were not associated with a higher rate of overall (HR: 0.90 95% CI: 0.90-1.17) and early tumour relapse (HR: 0.96 95% CI: 0.69-1.33).
(Singal AG et al. – Gastroenterology, May 2019)